The identification of TRK fusions in a variety of cancers have prompted the development of selective TRK inhibitors, such as larotrectinib or entrectinib, which have shown high response rates (≈75%) across children and adults with TRK-fusion cancers [67,68]. This evidence concerns the gene NTRK1 and cancer.